1 min listen
ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference
ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference
ratings:
Length:
13 minutes
Released:
May 30, 2024
Format:
Podcast episode
Description
Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm’s Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development of antibody drug conjugates, which is currently the hottest area in cancer treatment. Another highlight she expects from ASCO will be development in radiotherapy treatments, particularly in prostate cancer. Bardon provides a guide for attendees to use in setting their schedules for the year’s biggest cancer conference and what to watch for in the future.
Released:
May 30, 2024
Format:
Podcast episode
Titles in the series (38)
The BioWorld Insider Podcast - trailer by The BioWorld Insider Podcast